Evidence map›Paper›PMID 24586994›Full record

Trial reportPloS one2014

The effect of rosuvastatin on inflammation, matrix turnover and left ventricular remodeling in dilated cardiomyopathy: a randomized, controlled trial.

Kaspar Broch, Erik T Askevold, Erik Gjertsen, Thor Ueland, Arne Yndestad, Kristin Godang, Wenche Stueflotten, Johanna Andreassen, Rolf Svendsmark, Hans-Jørgen Smith and 3 more

Registry-linked trialOpen access · goldFull text readMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00505154 (A Phase III Study of the Effect of Rosuvastatin on Left Ventricular Remodeling and Inflammatory Markers in Heart Failure), which is not on this map. Cited by 5 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 2 pooled it
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00505154 phase3completednot on this map

A Phase III Study of the Effect of Rosuvastatin on Left Ventricular Remodeling and Inflammatory Markers in Heart Failure

TypeinterventionalSponsorOslo University HospitalRan2007 to 2013Enrolled75ConditionsDilated CardiomyopathyArmsRosuvastatin, placebo
3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 2 syntheses or guidelines pooled it, 11 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Observational
  4. Insights from Second-Line Treatments for Idiopathic Dilated Cardiomyopathy.Journal of cardiovascular development and disease · 2017
    Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

Kaspar BrochDepartment of Cardiology, Oslo University Hospital Rikshospitalet, Oslo, Norway ; Faculty of Medicine, University of Oslo, Oslo, Norway.
Erik T AskevoldDepartment of Cardiology, Oslo University Hospital Rikshospitalet, Oslo, Norway ; Research Institute of Internal Medicine, Oslo University Hospital Rikshospitalet, Oslo, Norway.
Erik GjertsenDepartment of Internal Medicine, Drammen Hospital, Vestre Viken Hospital Trust; Drammen, Norway.
Thor UelandResearch Institute of Internal Medicine, Oslo University Hospital Rikshospitalet, Oslo, Norway ; Faculty of Medicine, University of Oslo, Oslo, Norway.
Arne YndestadResearch Institute of Internal Medicine, Oslo University Hospital Rikshospitalet, Oslo, Norway.
Kristin GodangDepartment of Endocrinology, Oslo University Hospital Rikshospitalet, Oslo, Norway.
Wenche StueflottenDepartment of Cardiology, Oslo University Hospital Rikshospitalet, Oslo, Norway.
Johanna AndreassenDepartment of Cardiology, Oslo University Hospital Rikshospitalet, Oslo, Norway.
Rolf SvendsmarkDepartment of Radiology, Oslo University Hospital Rikshospitalet, Oslo, Norway.
Hans-Jørgen SmithDepartment of Radiology, Oslo University Hospital Rikshospitalet, Oslo, Norway ; Faculty of Medicine, University of Oslo, Oslo, Norway.
Svend AakhusDepartment of Cardiology, Oslo University Hospital Rikshospitalet, Oslo, Norway.
Pål AukrustResearch Institute of Internal Medicine, Oslo University Hospital Rikshospitalet, Oslo, Norway ; Section of Clinical Immunology and Infectious Diseases, Oslo University Hospital Rikshospitalet, Oslo, Norway ; Faculty of Medicine, University of Oslo, Oslo, Norway.
Lars GullestadDepartment of Cardiology, Oslo University Hospital Rikshospitalet, Oslo, Norway ; Faculty of Medicine, University of Oslo, Oslo, Norway ; K. G. Jebsen Cardiac Research Centre and Center for Heart Failure Research, Faculty of Medicine, University of Oslo, Oslo, Norway.
Oslo University Hospital · NOUniversity of Oslo · NODrammen Hospital · NO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDilated cardiomyopathy is characterized by left ventricular dilatation and dysfunction. Inflammation and adverse remodeling of the extracellular matrix may be involved in the pathogenesis. Statins reduce levels of low density lipoprotein cholesterol, but may also attenuate inflammation and affect matrix remodeling. We hypothesized that treatment with rosuvastatin would reduce or even reverse left ventricular remodeling in dilated cardiomyopathy. MATERIALS AND

methodsIn this multicenter, randomized, double blind, placebo-controlled study, 71 patients were randomized to 10 mg of rosuvastatin or matching placebo. Physical examination, blood sampling, echocardiography and cardiac magnetic resonance imaging were performed at baseline and at six months' follow-up. The pre-specified primary end point was the change in left ventricular ejection fraction from baseline to six months.

resultsOver all, left ventricular ejection fraction improved 5 percentage points over the duration of the study, but there was no difference in the change in left ventricular ejection fraction between patients allocated to rosuvastatin and those allocated to placebo. Whereas serum low density lipoprotein cholesterol concentration fell significantly in the treatment arm, rosuvastatin did not affect plasma or serum levels of a wide range of inflammatory variables, including C-reactive protein. The effect on markers of extracellular matrix remodeling was modest.

conclusionTreatment with rosuvastatin does not improve left ventricular ejection fraction in patients with dilated cardiomyopathy.

trial registrationClinicalTrials.gov NCT00505154.

Indexed as

AdultAgedCardiomyopathy, DilatedCholesterol, LDLExtracellular MatrixFemaleFluorobenzenesHeart FailureHumansHydroxymethylglutaryl-CoA Reductase InhibitorsInflammationMaleMiddle AgedPyrimidinesRosuvastatin CalciumSulfonamidesCholesterol, LDLFluorobenzenesHydroxymethylglutaryl-CoA Reductase InhibitorsPyrimidinesRosuvastatin CalciumSulfonamides

Identifiers

PMID24586994
PMCPMC3934914
OpenAlexW1969004872

What Socratic holds

Textfull text, public
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.